GLT8D2

Across TCGA pan-cancer cohorts, GLT8D2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GLT8D2 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GLT8D2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLT8D2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where GLT8D2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.291	0.894	.006	19	view →
LSCC	DFS	Tertile	All	0.810	1.000	.012	10	view →
LUAD	DFS	Quartile	III,IV	0.982	0.533	.031	5	view →
HNSC	OS	Quartile	All	0.958	0.818	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GLT8D2–PDAC (DFS)

Open the PDAC breakdown →